Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 10Gynecologic 5Plasma cell 3Breast 3Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2Gastrointestinal 2Thoracic 1Other 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × TIC10 compound × Endocrine × Clear all
NCT03034200 2024-11-26

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Case Comprehensive Cancer Center

Phase 2 Completed
30 enrolled 12 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡